Alector (ALEC): Genentech License Adds $100 Million Upfront

Why it is trending

Alector granted Genentech exclusive worldwide rights to AL050, an investigational enzyme-replacement therapy designed to reach the brain and address a mechanism linked to Parkinson’s disease. The agreement provides $100 million upfront, up to $1.17 billion in conditional development, regulatory and commercial milestones, and tiered sales royalties.

Genentech takes responsibility for development through commercialization, while Alector retains its brain-delivery platform. The milestone maximum depends on future achievements, and AL050 remains unapproved.

Sector

Health care and biotechnology. Alector develops treatments for neurodegenerative diseases and technology intended to transport therapeutic molecules across the blood-brain barrier.

Recent earnings

For Q2 2026, ended June 30, collaboration revenue was $3.3 million versus $7.9 million a year earlier. The GAAP net loss narrowed to $23.0 million, or $0.21 per share, from $30.5 million, or $0.30 per share.

A separate preliminary update estimated September 30 cash and investments at $138.7 million, or $223.7 million after giving pro forma effect to the Genentech and related Spur payments. Management now expects funding to last into 2029. The cash estimates are unaudited, and the funding outlook remains a forecast.

ATA Auto Trend Indicator Review

Alector’s current small green daily dots and larger green weekly dots show aligned BUY signals. The weekly timeframe represents the dominant trend. Both current bars are still forming, so these signals can change; the latest completed daily and weekly signals were also BUY. Earlier black dots are historical SELL signals.

Our proprietary ATA Auto Trend Indicator makes these signals easy to follow: small dots track daily buys and sells, while larger dots track weekly buys and sells. Green means buy; black means sell. The weekly timeframe represents the dominant trend. This clear visual approach helps you compare daily and weekly signals and support a more disciplined trading process.

WE PREPARE FOR THE NEXT MOVE RATHER THAN PREDICT IT.

Wednesday October 07, 2026